Related Experiment Video
Updated: Feb 10, 2026
09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
2.3K
Drug interaction screening in SWOG clinical trials
Daniel L Hertz1, Rivka Siden2, Jessie Modlin3
1Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI dlhertz@med.umich.edu.
Summary
Drug interaction screening in SWOG clinical trials is not systematic. Clinical research coordinators and nurses primarily perform this, with limited pharmacist involvement, impacting patient safety during trial enrollment.
Area of Science:
- Clinical Pharmacy
- Oncology Clinical Trials
- Drug Safety
Background:
- Systematic drug interaction (DI) screening is crucial for patient safety in clinical trials.
- SWOG clinical trials involve complex patient populations and polypharmacy, increasing the risk of drug interactions.
Purpose of the Study:
- To investigate the current practices and frequency of drug interaction screening among sites participating in SWOG clinical trials.
- To identify the personnel involved in drug interaction assessment during patient screening and enrollment.
Main Methods:
- A survey was distributed to 180 SWOG head clinical research associates.
- Data on the frequency and process of DI screening were collected and analyzed using descriptive statistics.
Main Results:
- A 46.1% response rate was achieved, with 72 completed surveys.
- 51% of sites screened for DIs only when specified in exclusion criteria.
- Pharmacist involvement was infrequent (17% always involved); clinical research coordinators and nurses were the primary screeners.
Conclusions:
- Drug interaction screening is not consistently performed across SWOG clinical trial sites.
- The current practice relies heavily on non-pharmacist personnel, indicating a gap in systematic DI assessment.
- Limited pharmacist availability and involvement hinder pharmacist-led DI screening in SWOG sites.
Related Concept Videos
01:16Clinical Trials
10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.9K
01:11Clinical Trials: Overview
5.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
01:12Statistical Software for Data Analysis and Clinical Trials
1.6K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.6K
01:25Pharmacokinetics: Drug–Drug Interactions
462
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
462
01:29Drug-Receptor Interactions
7.6K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.6K
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
611
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
611